OBJECTIVE: To investigate whether CD40L/CD154 on platelets and soluble CD40L/CD154 may play a role in the inflammatory process of acute coronary syndromes. DESIGN AND SETTING: Observational study in a university hospital. PATIENTS: 15 patients with acute myocardial infarction, 25 patients with unstable angina, 15 patients with stable angina, and 12 controls. MAIN OUTCOME MEASURES: CD40L/CD154 on platelets, P-selectin/CD62P on platelets, soluble CD40L/CD154 serum concentrations. RESULTS: Mean (SD) CD40L/CD154 expression on platelets was 6.2 (2.8) MFI (mean fluorescence intensity) in the infarct group, 11 (3.3) MFI in the unstable angina group (p < 0.001 v infarction), 3.6 (0.9) MFI in the stable angina group (p < 0.01 v infarction; p < 0.001 v unstable angina), and 3.2 (1.0) MFI in the controls (p < 0.01 v infarction; p < 0.001 v unstable angina; NS v stable angina). Soluble CD40L/CD154 concentration was 5.2 (1.1) ng/ml in the infarct group, 4.2 (0.7) ng/ml in the unstable angina group (p < 0.001 v infarction), 2.9 (1.0) ng/ml in stable angina group (p < 0.001 v infarction and unstable angina), and 3.0 (0.5) ng/ml in the controls (p < 0.001 v infarction and unstable angina; NS v stable angina). At a six months follow up, there was lower expression of CD40L/CD154 on platelets in patients with unstable angina (12.3 (3.6) v 3.8 (1.2) MFI, p < 0.0001) and acute myocardial infarction (6.2 (2.8) v 3.5 (0.8) MFI, p < 0.01) compared with their admission values six months earlier. Patients with unstable angina who needed redo coronary angioplasty (PTCA) or who had recurrence of angina were characterised by increased CD40L/CD154 expression on platelets compared with the remainder of the study group (recurrence of angina: 12.7 (3.2) v 9.7 (1.6) MFI, p < 0.05; re-do PTCA: 14.3 (4.2) v 10.3 (2.1) MFI, p < 0.05). CONCLUSIONS: Both CD40L/CD154 on platelets and soluble CD40L/CD154 are raised in patients with unstable angina and myocardial infarction. These findings suggest that CD40-CD40L/CD154 interactions may play a pathogenic role in triggering and propagation of acute coronary syndromes.
OBJECTIVE: To investigate whether CD40L/CD154 on platelets and soluble CD40L/CD154 may play a role in the inflammatory process of acute coronary syndromes. DESIGN AND SETTING: Observational study in a university hospital. PATIENTS: 15 patients with acute myocardial infarction, 25 patients with unstable angina, 15 patients with stable angina, and 12 controls. MAIN OUTCOME MEASURES: CD40L/CD154 on platelets, P-selectin/CD62P on platelets, soluble CD40L/CD154 serum concentrations. RESULTS: Mean (SD) CD40L/CD154 expression on platelets was 6.2 (2.8) MFI (mean fluorescence intensity) in the infarct group, 11 (3.3) MFI in the unstable angina group (p < 0.001 v infarction), 3.6 (0.9) MFI in the stable angina group (p < 0.01 v infarction; p < 0.001 v unstable angina), and 3.2 (1.0) MFI in the controls (p < 0.01 v infarction; p < 0.001 v unstable angina; NS v stable angina). Soluble CD40L/CD154 concentration was 5.2 (1.1) ng/ml in the infarct group, 4.2 (0.7) ng/ml in the unstable angina group (p < 0.001 v infarction), 2.9 (1.0) ng/ml in stable angina group (p < 0.001 v infarction and unstable angina), and 3.0 (0.5) ng/ml in the controls (p < 0.001 v infarction and unstable angina; NS v stable angina). At a six months follow up, there was lower expression of CD40L/CD154 on platelets in patients with unstable angina (12.3 (3.6) v 3.8 (1.2) MFI, p < 0.0001) and acute myocardial infarction (6.2 (2.8) v 3.5 (0.8) MFI, p < 0.01) compared with their admission values six months earlier. Patients with unstable angina who needed redo coronary angioplasty (PTCA) or who had recurrence of angina were characterised by increased CD40L/CD154 expression on platelets compared with the remainder of the study group (recurrence of angina: 12.7 (3.2) v 9.7 (1.6) MFI, p < 0.05; re-do PTCA: 14.3 (4.2) v 10.3 (2.1) MFI, p < 0.05). CONCLUSIONS: Both CD40L/CD154 on platelets and soluble CD40L/CD154 are raised in patients with unstable angina and myocardial infarction. These findings suggest that CD40-CD40L/CD154 interactions may play a pathogenic role in triggering and propagation of acute coronary syndromes.
Authors: E Lutgens; L Gorelik; M J Daemen; E D de Muinck; I S Grewal; V E Koteliansky; R A Flavell Journal: Nat Med Date: 1999-11 Impact factor: 53.440
Authors: L M Biasucci; G Liuzzo; G Fantuzzi; G Caligiuri; A G Rebuzzi; F Ginnetti; C A Dinarello; A Maseri Journal: Circulation Date: 1999-04-27 Impact factor: 29.690
Authors: P Aukrust; F Müller; T Ueland; T Berget; E Aaser; A Brunsvig; N O Solum; K Forfang; S S Frøland; L Gullestad Journal: Circulation Date: 1999-08-10 Impact factor: 29.690
Authors: E Lutgens; K B Cleutjens; S Heeneman; V E Koteliansky; L C Burkly; M J Daemen Journal: Proc Natl Acad Sci U S A Date: 2000-06-20 Impact factor: 11.205
Authors: K Kato; E Santana-Sahagún; L Z Rassenti; M H Weisman; N Tamura; S Kobayashi; H Hashimoto; T J Kipps Journal: J Clin Invest Date: 1999-10 Impact factor: 14.808
Authors: N Katakami; H Kaneto; M Matsuhisa; T Miyatsuka; K Sakamoto; D Kawamori; K Yoshiuchi; Y Nakamura; K Kato; K Yamamoto; K Kosugi; M Hori; Y Yamasaki Journal: Diabetologia Date: 2006-05-12 Impact factor: 10.122
Authors: Jill M Cholette; Neil Blumberg; Richard P Phipps; Michael P McDermott; Kelly F Gettings; Norma B Lerner Journal: J Pediatr Date: 2007-10-24 Impact factor: 4.406
Authors: Budi Y Setianto; Anggoro B Hartopo; Putrika P R Gharini; Dyah W Anggrahini; Bambang Irawan Journal: Heart Vessels Date: 2010-07-31 Impact factor: 2.037
Authors: K S Srinivasa Prasad; Patrick Andre; Ming He; Ming Bao; Jeanne Manganello; David R Phillips Journal: Proc Natl Acad Sci U S A Date: 2003-09-30 Impact factor: 11.205